Skip to main content
. 2014 Aug 29;124(16):2544–2553. doi: 10.1182/blood-2013-12-546309

Figure 4.

Figure 4

Prevalence of nonsilent mutations in CD70, TMSB4X, B2M, DTX1, UBE2A, and LYN in an extended cohort of DLBCL patients (n = 136). CD70 was the most frequent mutation target in the present cohort. TMSB4X and LYN are novel mutation targets in DLBCL.